Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are now recruiting volunteers for Oxford Vaccine Group's new Ebola study: Evaluating Optimal Vaccine Schedules against Ebola (EVOLVE)

RECRUITING NOW!

You are invited to take part in a study investigating new vaccines against Ebola virus disease (EVD). The current outbreak of EVD in West Africa is estimated by the World Health Organization to have caused more than 10,000 deaths to date and is still ongoing. There is no specific treatment or cure for Ebola and an effective vaccine would be an important step in controlling the spread of disease. The study is being run by the Oxford Vaccine Group, part of the University of Oxford. 

►       If you are aged 18 to 65 years old and in good health you may be eligible to take part in the study

►       We will provide reimbursement for your time, inconvenience and travel

Interested individuals may attend a screening visit at our site to discuss this further and for their suitability for the study to be assessed.  If you would like to find out more, you can contact us via:

Ebolavaccine.org.uk

01865 857420

info@ovg.ox.ac.uk


This study is being run by the Oxford Vaccine Group, part of the University of Oxford and is funded by Crucell Holland BV.

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.